SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Service Sectors > Analytical testing, QC

Loading...

Covance adding mass spec for biosimilars

By Nick Taylor , 23-Nov-2011
Last updated on 23-Nov-2011 at 13:52 GMT2011-11-23T13:52:15Z

Covance is adding mass spectrometry and other capabilities to meet growing demand for biosimilar comparability services.

Efforts to create a pathway for biosimilars in the US have attracted generics companies, big biopharm and virtual biotechs. This has created opportunities for contract research organisations (CROs).

What’s really big right now is the biosimilar market. So what we’re developing is the ability to do high-level structural characterisation”, Ray Kaiser, chief scientific officer, biotechnology at Covance, told Outsourcing-Pharma.

Covance is adding expertise in mass spectrometry and physical chemical analyses to help clients assess the comparability of biosimilars to innovator molecules. Some of these clients are virtual biotechs that need more guidance through the drug development process than larger companies.

Related products

William Reed Business Media Holiday video

Happy Holidays 2014 from William Reed Business Media!

The holidays are fast upon us, so let’s put ‘business’ to one side and...

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

A bitter pill to swallow: young people dislike tablets more than old

A bitter pill to swallow: young people dislike tablets more than old

Thomas Hein

Director, Sales & Business Development, Hermes

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Key Industry Events

 

Access all events listing

Our events, Events from partners...